Lipopeptide- and lipoprotein-conjugates and its use

US10918733B2 · kind B2 · utility

Assignee

• Helmholtz-Zentrum Für Infektionsforschung GmbH · DE

Inventors

• Thomas Ebensen · Hannover, DE
• Carlos Guzman · Wolfenbüttel, DE
• Michael Morr · Wolfenbüttel, DE
• Werner Tegge · Braunschweig, DE

Key dates

• Filing date: Dec 28, 2010
• Grant date: Feb 16, 2021
• Expiry date: Dec 28, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates. In particular, the present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates comprising a lipid-containing moiety representing an adjuvant moiety, a peptide or protein moiety whereby said peptide or protein moiety represents at least one antigenic structure, the antigen-moiety, and, optionally, a conjugate moiety, preferably a monodisperse polyethyleneglycol unit.Said compounds are particularly useful for therapeutic or prophylactic vaccination by mucosal or systemic administration, preferably mucosal and systemic vaccination. That is, the present invention relates in another aspect to pharmaceutical compositions comprising the compounds according to the present invention, in particular, said pharmaceutical compositions are vaccines. In addition, said pharmaceutical compositions are useful for the prophylaxis or treatment of infectious diseases, inflammatory and autoimmune diseases, cancer, allergies or for the control of fertility in human or animal populations.